Thu, Oct 30, 2014, 2:26 PM EDT - U.S. Markets close in 1 hr 34 mins

Recent

% | $
Quotes you view appear here for quick access.

ArQule Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • pharmainvestor11 pharmainvestor11 Jan 20, 2012 7:34 PM Flag

    Investor Conference Call on 1/17

    the ARQL situation is quite simple:
    - HCC indication is a quite sizable market without any 2d-line treatments
    - designing their 2d-line PhII HCC trial, the company did not expected to get good results. consequently, there was no attempt to go for a PhII registration trial (small number of pts with allowed crossovers
    - the HCC monotherapy results have met primary TTP stag-sig goals with respectable HR=0.67 and p=0.04
    - due to crossovers, OS will not have a placebo baseline but can be compared with available literature data
    - RR will be of great interest. if data are good, many inoperable pts can become eligible for a surgery

    The bottom line
    If HCC data are good, ARQL can become a $1.0+ market cap company after ASCO. Registration quality NSCLC data will drive ARQL's MC well over $2.5B

 
ARQL
1.18+0.01(+0.85%)2:09 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.